Intrinsic immunity of ALK-mutant and ALK-non-mutant tumors. (IMAGE)
Caption
(A) Comparison of TMB, non-silent mutation rate, and silent mutation rate between ALK-mutant and ALK-non-mutant tumors. (B) The illustrations of six identified SBS signatures related to ALK mutation and their frequencies in ALK-mutant and ALK-non-mutant tumors. Bold black, SBS signature and its known etiologies; green, frequency in ALK-mutant cancer; orange, frequency in ALK-non-mutant cancer. (C) The associations between identified mutation signatures and overall survival in pan-cancer immunotherapy. (D) Differences of 16 MHC-related antigen-presenting molecules (including 5 MHC I molecules, 7 MHC II molecules, and 4 other MHC molecules) and 25 co-stimulators between ALK-mutant and ALK-non-mutant tumors. The color scheme indicates the median value difference of the normalized gene expression between ALK-mutant and ALK-non-mutant tumors. ALK, anaplastic lymphoma kinase; MHC, major histocompatibility complex; SBS, single base substitution; TMB, tumor mutation burden.
Credit
Zhiyang Huang, Jiajun Chen, Yan Huang, Hong Zhao, Bin Zhao
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND